image
Healthcare - Biotechnology - NASDAQ - US
$ 1.75
-0.52 %
$ 584 M
Market Cap
-1.43
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one IOVA stock under the worst case scenario is HIDDEN Compared to the current market price of 1.75 USD, Iovance Biotherapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one IOVA stock under the base case scenario is HIDDEN Compared to the current market price of 1.75 USD, Iovance Biotherapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one IOVA stock under the best case scenario is HIDDEN Compared to the current market price of 1.75 USD, Iovance Biotherapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart IOVA

image
$6.5$6.5$6.0$6.0$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
164 M REVENUE
13698.99%
-395 M OPERATING INCOME
14.17%
-372 M NET INCOME
16.18%
-353 M OPERATING CASH FLOW
2.44%
-96.4 M INVESTING CASH FLOW
37.90%
391 M FINANCING CASH FLOW
-15.62%
49.3 M REVENUE
-33.07%
-121 M OPERATING INCOME
-40.02%
-116 M NET INCOME
-47.87%
-104 M OPERATING CASH FLOW
-41.47%
15.9 M INVESTING CASH FLOW
-32.99%
143 M FINANCING CASH FLOW
6106.80%
Balance Sheet Iovance Biotherapeutics, Inc.
image
Current Assets 457 M
Cash & Short-Term Investments 324 M
Receivables 69.3 M
Other Current Assets 63.9 M
Non-Current Assets 453 M
Long-Term Investments 0
PP&E 164 M
Other Non-Current Assets 289 M
35.56 %7.62 %7.02 %18.04 %31.76 %Total Assets$910.4m
Current Liabilities 122 M
Accounts Payable 27.5 M
Short-Term Debt 12.9 M
Other Current Liabilities 81.9 M
Non-Current Liabilities 77.7 M
Long-Term Debt 45.4 M
Other Non-Current Liabilities 32.3 M
13.75 %6.45 %40.96 %22.68 %16.16 %Total Liabilities$200.0m
EFFICIENCY
Earnings Waterfall Iovance Biotherapeutics, Inc.
image
Revenue 164 M
Cost Of Revenue 124 M
Gross Profit 40.1 M
Operating Expenses 435 M
Operating Income -395 M
Other Expenses -23.1 M
Net Income -372 M
200m200m100m100m00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)164m(124m)40m(435m)(395m)23m(372m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
24.43% GROSS MARGIN
24.43%
-240.92% OPERATING MARGIN
-240.92%
-226.84% NET MARGIN
-226.84%
-52.39% ROE
-52.39%
-40.88% ROA
-40.88%
-48.98% ROIC
-48.98%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Iovance Biotherapeutics, Inc.
image
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)(350m)(350m)(400m)(400m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -372 M
Depreciation & Amortization 31.6 M
Capital Expenditures -11.1 M
Stock-Based Compensation 110 M
Change in Working Capital -123 M
Others -5.61 M
Free Cash Flow -364 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Iovance Biotherapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for IOVA of $12.8 , with forecasts ranging from a low of $2 to a high of $24 .
IOVA Lowest Price Target Wall Street Target
2 USD 14.29%
IOVA Average Price Target Wall Street Target
12.8 USD 630.61%
IOVA Highest Price Target Wall Street Target
24 USD 1271.43%
Price
Max Price Target
Min Price Target
Average Price Target
25252020151510105500Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership Iovance Biotherapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
503 K USD 1
9-12 MONTHS
0 USD 0
Bought
107 K USD 3
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
IOVA SHAREHOLDER ALERT: Suffer Losses on Iovance Biotherapeutics? Contact BFA Law by July 14 Securities Fraud Class Action Deadline (NASDAQ:IOVA) Iovance Biotherapeutics, Inc. investors that lost money are notified to contact BFA Law before the July 14, 2025 securities fraud class action deadline. globenewswire.com - 1 week ago
Is This Beaten-Down Stock a Millionaire Maker? Over the past two years, Iovance Biotherapeutics (IOVA), a small-cap biotech company, has made significant clinical and regulatory progress. However, the stock has also plunged over this period -- shares are currently trading for less than $2 apiece. fool.com - 1 week ago
IOVA DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – IOVA NEW YORK, July 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”), of the important July 14, 2025 lead plaintiff deadline. globenewswire.com - 1 week ago
Levi & Korsinsky Reminds Iovance Biotherapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 14, 2025 – IOVA NEW YORK, July 03, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit. globenewswire.com - 2 weeks ago
IOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit NEW YORK, July 03, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or “the Company”) (NASDAQ: IOVA) and certain of its officers. globenewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA NEW YORK, July 03, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA). Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. globenewswire.com - 2 weeks ago
The Gross Law Firm Reminds Iovance Biotherapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 14, 2025 - IOVA NEW YORK , July 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). Shareholders who purchased shares of IOVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. prnewswire.com - 2 weeks ago
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Losses In Iovance To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in  Iovance  between August 8, 2024 and May 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). [You may also click here for additional information] NEW YORK , July 3, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) and reminds investors of the July 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. prnewswire.com - 2 weeks ago
Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure– Hagens Berman IOVA Investors with Losses Encouraged to Contact Hagens Berman Before July 14th Deadline IOVA Investors with Losses Encouraged to Contact Hagens Berman Before July 14th Deadline globenewswire.com - 2 weeks ago
Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Firm NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). globenewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA). Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. prnewswire.com - 2 weeks ago
IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV LOS ANGELES , July 2, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ: IOVA) for violations of the federal securities laws. Shareholders who purchased the Company's securities between May 9, 2024 and May 8, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before July 14, 2025. prnewswire.com - 2 weeks ago
8. Profile Summary

Iovance Biotherapeutics, Inc. IOVA

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 584 M
Dividend Yield 0.00%
Description Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Contact 825 Industrial Road, San Carlos, CA, 94070 https://www.iovance.com
IPO Date Oct. 15, 2010
Employees 838
Officers Dr. Igor P. Bilinsky Ph.D. Chief Operating Officer Ms. Sara Pellegrino Senior Vice President of Investor Relations & Corporate Communications Ms. Tracy Winton Executive Vice President of Human Resources Dr. Friedrich Graf Finckenstein M.D. Chief Medical Officer Dr. Raj K. Puri M.D., Ph.D. Chief Regulatory Officer Mr. Howard B. Johnson M.B.A. Chief Business Officer Mr. Kevin Smyth Executive Vice President of Quality Dr. Frederick G. Vogt Esq., J.D., Ph.D. Interim Chief Executive Officer, President, General Counsel, Corporate Secretary & Director Mr. Jean-Marc Bellemin M.B.A. Chief Financial Officer, Principal Accounting Officer & Treasurer Mr. Brian Shew M.B.A. Senior Vice President & Head of Digital and Information Technology